Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 1.00 |
| ▸ | PIK3R2 | O00459 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 20/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 20/20 | 1.00 |
| ▸ | PIK3R5 | Q8WYR1 | 20/20 | 1.00 |
| ▸ | PIK3R3 | Q92569 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roginolisib SCHEMBL29515379 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| Roginolisib SCHEMBL15942124 | 0.93 | PIK3CD (0.87) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL14782 | 0.92 | PIK3CD (0.86) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| Roginolisib SCHEMBL15942390 | 0.92 | PIK3CD (0.84) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL30174992 | 0.92 | PIK3CD (0.84) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL30460537 | 0.92 | PIK3CD (0.84) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL25224835 | 0.91 | PIK3CD (0.83) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL30443259 | 0.91 | PIK3CD (0.83) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL12878 | 0.91 | PIK3CD (0.83) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL12581 | 0.90 | PIK3CD (0.81) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014121901-A1 | POLYMORPHIC FORMS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | claimed |
| EP-4744651-A2 | A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS | iOnctura SA (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727554-A1 | COMBINATIONS OF IOA-244, A PD-1 OR PD-L1 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT TO TREAT CANCER | iOnctura SA (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12605389-B2 | PI3K-δ inhibitor for use in treatment regimens | IONCTURA SA (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-4676478-A1 | COMBINATION OF ROGINOLISIB AND BCL-2 INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676454-A1 | COMBINATION OF ROGINOLISIB AND HDAC INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025073968-A1 | COMBINATION OF ROGINOLISIB WITH A MALT1-GLS INHIBITOR | IONCTURA SA (CH) | 2025-04-10 | — | — | WO | disclosed |
| EP-4313058-B1 | COMPOSITION COMPRISING ROGINOLISIB AND DOSAGE REGIME FOR TREATING CANCER OR AN INFLAMMATORY OR AUTOIMMUNE DISEASE | IONCTURA SA (CH) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024256552-A1 | COMBINATIONS OF IOA-244, A PD-1 OR PD-L1 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT TO TREAT CANCER | IONCTURA SA (CH) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024184266-A1 | COMBINATION OF ROGINOLISIB AND HDAC INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | IONCTURA SA (CH) | 2024-09-12 | — | — | WO | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| WO-2014121901-A1 | POLYMORPHIC FORMS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014121901-A1 | POLYMORPHIC FORMS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605389-B2 | PI3K-δ inhibitor for use in treatment regimens | PIK3CD, PIK3R5, PIK3R4 | PIK3CD 1/4885PIK3R2 7/4885PIK3CA 6/4885 |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | PIK3CD 5/4885PIK3R2 27/4885PIK3CA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.